Erythromycin A produced in E. coli for first time: Biosynthetic breakthrough paves way for other pharmaceuticals

For the first time, researchers have made the antibiotic erythromycin A, and two variants, using E. coli as the production host. This is a cost-effective way to make erythromycin A and new drugs to combat antibiotic resistant pathogens. The E. coli host also offers next-generation engineering opportunities for other products with complex biosynthetic pathways.